Consortium of 900 hospital systems in 46 states involved
Lehi is the new home and headquarters for
Civica Rx, a not-for-profit company, formed by a collection of hospitals, which
supplies generic medications. A grand opening and ribbon cutting ceremony held
on April 18, was attended by Utah Governor, Gary Herbert, U.S. Congressman, Ben
Adams as well as hospital and university officials.
Lehi was chosen because it is centrally
located amid Utah’s major universities and has become a hub for Utah’s startup
and tech communities. The location will also enable Civica Rx to draw on local
expertise and talent. The Lehi office will house about 40 people soon and
expansion opportunities in Lehi are expected to bring the office to four or
five times that size within three to five years, according to a press release.
Civica Rx has 900 participating health systems in 46 states. In Utah, those
participating hospitals include Intermountain Healthcare, MountainStar, Steward
Health Care and University of Utah Health, according to Debbi Ford, Chief
Communications and Public Affairs Officer.
“Today’s opening of Civica Rx’s Utah
headquarters in Lehi is a milestone in the effort to reduce chronic drug
shortages in healthcare institutions across the country,” posted Intermountain
on their twitter account.
Civica Rx mission is to stabilize the supply
of generic medications and reduce chronic generic drug shortages which have
become a national crisis, said Martin VanTrieste, Civica Rx CEO. “Drug
shortages strain hospital staff and lead to delayed surgeries and sub-optimal
treatment for patients and can lead to unpredictable price increases that
result in budgetary instability in hospitals,” said VanTrieste.
The company plans to focus on producing drugs
that are often on the FDA shortlist as well as on hospital-based medicines,
which are mostly sterile injectables, such as anesthesia medications,
antibiotics, pain medications, nutrients, and electrolytes, he said. Civica Rx,
with the assistance of the Drug Selection Advisory Committee, will prioritize
the medicines they will make, although no specific drugs have been announced
yet.